Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study.
Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study.
复制标题
DOI：
10.18632/oncotarget.26145
复制
发表时间：
2018-10-02
期刊：
影响因子：
--
通讯作者：
Yasui H
中科院分区：
文献类型：
--
作者：
Ogata T;Satake H;Ogata M;Hatachi Y;Inoue K;Hamada M;Yasui H
嗜中性粒细胞与淋巴细胞比率（NLR）作为用纳武单抗治疗的肺癌的预测因子是有效的。本研究的目的是确定NLR对接受nivolumab治疗的晚期胃癌（AGC）患者的有效性。这是一项在2017年6月至2017年12月接受nivolumab治疗的AGC患者中进行的多中心回顾性研究。在第一个周期前（NLR前）和首次给药后2周（NLR后）计算NLR。入组26例患者（男性19例，女性7例），中位年龄为64岁。总有效率为15%。中位PFS为80天（范围，11 - 265），中位OS为290天（范围，21 - 332）。按高NLR（≥5）和低NLR（<5）分层，高NLR治疗前组的中位PFS较短（87 vs. 45天; p=0.066），高NLR治疗后组的中位PFS显著较短（94 vs. 28天; p=0.014）。高NLR治疗前组（290 vs. 175天; p=0.008）和高NLR治疗后组（290 vs. 69天; p<0.001）的中位OS显著缩短。NLR可能是接受纳武利尤单抗治疗的AGC患者的有效预后因素。
The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab. This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLRpre) and two weeks after the first administration (NLRpost). Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 – 265) and the median OS was 290 days (range, 21 – 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLRpre arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLRpost arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLRpre arm (290 vs. 175 days; p=0.008) and in the high NLRpost arm (290 vs. 69 days; p<0.001). NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.